Evolent Bets on AI-Led Operations as It Raises 2026 Revenue Outlook
Evolent raised its 2026 revenue guidance after reporting 47% revenue growth in Q2, with executives pointing to an AI-led operating model and new oncology partnerships.
Where global leaders learn how AI shapes business, technology and society
Evolent raised its 2026 revenue guidance after reporting 47% revenue growth in Q2, with executives pointing to an AI-led operating model and new oncology partnerships.
"This new experience on the Hers app embeds intelligence at every step of the care experience."
"Morrisons recognize that the best AI solutions deliver measurable results without compromising the customer experience."
"AI is not just making the same projects faster, it is making thousands of projects viable that never were before."
"AI presents new opportunities to deliver more seamless experiences and greater value for the clients, agents and advisors who rely on New York Life."
Astrana Health raised its 2026 EBITDA outlook after reporting strong second-quarter growth driven by its AI-native healthcare platform.
The company’s latest earnings suggest enterprise AI spending is expanding beyond knowledge workers into frontline operations across warehouses, hospitals, factories, and retail stores.
"Businesses are increasingly looking for ways to improve customer experiences while optimizing working capital."
Chris Davis-Pipe and Antony Anand on Crown's data rules, and why the company still asks "why" before it digitizes anything.
"We are on a mission to power our customers at every touchpoint with AI to deliver a seamless shopping experience."
The firms that mapped AI disruption across every industry are now experiencing it in their own distribution model.
Power generation sales to users climbed 72% in the second quarter as Caterpillar resumes production of a gas engine platform discontinued in 2022.
Lumen reported Q2 results in line with expectations as strategic revenue exceeded half of business revenue and AI-focused networking services gained momentum.
Eli Lilly and Novartis spent little time discussing quarterly earnings, focusing instead on R&D, acquisitions, and the next generation of medicines.
"AI is at the heart of our momentum and is a clear accelerant for our business."
GenScript and Tamarind Bio have partnered to connect AI-powered molecular design with wet-lab validation, aiming to help researchers evaluate drug candidates faster.
The appointment comes as the company expands its use of artificial intelligence across clinical research and drug development workflows.
"I look forward to partnering with our teams around the world to deliver greater value for customers facing increasingly complex challenges."
The new ShipBob MCP offers 70+ read and write actions across 10 areas of operations, among the first full read-write connectors in the fulfillment industry.
"BioCatch will help our clients stop fraud before it reaches the point of payment."